Salveen Richter

There is continued upside to the consensus estimates for Amgen Inc's (NASDAQ:AMGN) earnings in fiscal 2026 and beyond due to execution across its portfolio, according to Goldman Sachs. The Amgen Analyst: Analyst Salveen Richter reiterated a Buy rating and a $403 price target. The Amgen Thesis:...

Amgen Inc‘s (NASDAQ:AMGN) second quarter results demonstrate ongoing development of its late-stage pipeline “to offset end-of-decade losses-of-exclusivity," according to Goldman Sachs. The Amgen Analyst: Goldman Savhs analyst Salveen Richter reiterated a Buy rating, while raising the...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) last week announced that the Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR) had met its primary endpoint. The company announced that the FDA had approved Alyftrek (or vanzacaftor triple) in cystic fibroris (CF) six years and older,...

Intellia Therapeutics Inc (NASDAQ: NTLA) is trading significantly higher Monday morning after the company announced positive clinical data for its CRISPR therapy. What Happened: Intellia and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) reported positive interim data from an ongoing Phase...

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares came under pressure Monday after the Food and Drug Administration (FDA) rejected its regulatory application seeking label expansion for its dementia drug. The Acadia Analysts: Goldman Sachs analyst Salveen Richter downgraded Acadia shares...

Moderna Inc (NASDAQ: MRNA) shares were trading at new highs Monday following the release of positive interim Phase 1 immunogenicity and safety data for its mRNA-1273 coronavirus vaccine candidate.  The Moderna Analysts Goldman Sachs analyst Salveen Richter maintained a Buy rating on Moderna...

Crispr Therapeutics AG (NASDAQ: CRSP) has surged 24 percent since the start of the year, but one analyst sees little more room to run. The Rating Goldman Sachs analyst Salveen Richter downgraded Crispr to Neutral and cut his price target from $78 to $40. The Thesis Richter considers Crispr a...

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) reported top- and bottom-line beats last week that prompted two Street analysts to upgrade the stock. The Rating Goldman Sachs analyst Salveen Richter upgraded Intercept from Sell to Buy and more than tripled the price target from $46 to $157....

Madrigal Pharmaceuticals Inc (NASDAQ: MDGL), a clinical-stage biotechnology company, could spring a surprise in the non-alcoholic steatohepatitis, or NASH, space, according to Goldman Sachs.  The Analyst Analyst Salveen Richter initiated coverage of Madrigal with a Buy rating and...

Just weeks into its life as a publicly traded company, Solid Biosciences Inc (NASDAQ: SLDB) caught the eyes of four analysts who assumed coverage Tuesday with a mix of Holds and Buys. Here is what one of the more bearish critics had to say. The Rating Goldman Sachs analyst Salveen Richter...

Denali Therapeutics Inc. (NASDAQ: DNLI), a biotech company focusing on therapies for neurodegenerative disorders, IPO-ed in Dec. 2017, offering 13.9 million shares at $18 each.  The Analyst Goldman Sachs analyst Salveen Richter initiated coverage of Denali Therapeutics with a...

Goldman Sachs is downgrading Spark Therapeutics Inc (NASDAQ: ONCE) after the pharma startup presented disappointing data on its hemophilia A gene therapy at the annual meeting of the American Society of Hematology on Monday. The Analyst Goldman Sachs' Salveen Richter downgraded Spark...

Shares of cannabinoid-focused biotech company GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) are "on a path to new highs," according to Goldman Sachs. The Analyst Goldman Sachs analyst Salveen Richter upgraded GW Pharma from Neutral to Buy and lifted her price target to $174, suggesting...

Bluebird bio Inc (NASDAQ: BLUE)'s multiple myeloma therapy coud have a "disruptive impact" on treatment of the disease, according to Goldman Sachs. The Analyst Goldman Sachs' Salveen Richter maintains a Buy rating on bluebird's stock and raised the price target from $186 to...